Non-alcoholic Steatohepatitis (NASH) Market Size 2026-2030
The non-alcoholic steatohepatitis (nash) market size is valued to increase by USD 40.06 billion, at a CAGR of 47.1% from 2025 to 2030. Rising prevalence of obesity and metabolic syndrome will drive the non-alcoholic steatohepatitis (nash) market.
Major Market Trends & Insights
- North America dominated the market and accounted for a 52% growth during the forecast period.
- By Distribution Channel - Offline segment was valued at USD 4.14 billion in 2024
- By Application - Diagnosis segment accounted for the largest market revenue share in 2024
Market Size & Forecast
- Market Opportunities: USD 45.49 billion
- Market Future Opportunities: USD 40.06 billion
- CAGR from 2025 to 2030 : 47.1%
Market Summary
- The non-alcoholic steatohepatitis (NASH) market is undergoing a significant transformation, moving from a research-focused field to a commercially viable sector. This shift is primarily driven by the escalating global incidence of metabolic syndrome components and a deeper understanding of the disease's progression toward cirrhosis.
- Key trends include the development of non-invasive biomarkers for early diagnosis and the exploration of combination therapy approaches to address the multifaceted nature of the disease. However, the complexity of achieving histological endpoints like nash resolution and fibrosis improvement presents a substantial challenge.
- For instance, a healthcare system can leverage new diagnostic tools like magnetic resonance elastography to proactively screen at-risk populations. This strategy enables earlier intervention, optimizes the allocation of hepatology resources, and informs formulary decisions for upcoming pharmacotherapies, ultimately improving patient outcomes related to cirrhosis prevention and reducing long-term healthcare costs.
- The focus on the gut-liver axis modulation is also opening new avenues for therapeutic intervention.
What will be the Size of the Non-alcoholic Steatohepatitis (NASH) Market during the forecast period?
Get Key Insights on Market Forecast (PDF) Request Free Sample
How is the Non-alcoholic Steatohepatitis (NASH) Market Segmented?
The non-alcoholic steatohepatitis (nash) industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD million" for the period 2026-2030, as well as historical data from 2020-2024 for the following segments.
- Distribution channel
- Offline
- Online
- Application
- Diagnosis
- Treatment
- Product
- Vitamin E and pioglitazone
- Obeticholic acid (OCA)
- Lanifibranor
- Others
- Geography
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Asia
- Rest of World (ROW)
- North America
By Distribution Channel Insights
The offline segment is estimated to witness significant growth during the forecast period.
Offline channels remain fundamental for the global non-alcoholic steatohepatitis (nash) market 2026-2030, particularly for the delivery of complex therapeutics and precision-guided diagnostics.
Healthcare facilities are critical hubs for administering emerging treatments, including farnesoid x receptor agonist and peroxisome proliferator-activated receptor therapies, which require professional oversight. The management of this condition necessitates in-person consultations for therapeutic monitoring solutions and adapting off-label pharmacotherapy.
Moreover, advanced drug discovery platforms are yielding incretin-based metabolic therapies and agents like apoptosis signal-regulating kinase 1 inhibitor and caspase inhibitors, whose initial deployment relies on established clinical infrastructure.
Patient adherence to these targeted therapeutic mechanisms improves by over 20% with regular, face-to-face provider interactions, reinforcing the value of this segment for managing novel treatments such as acetyl-coa carboxylase inhibitors and thyroid hormone receptor-beta agonist.
The Offline segment was valued at USD 4.14 billion in 2024 and showed a gradual increase during the forecast period.
Regional Analysis
North America is estimated to contribute 52% to the growth of the global market during the forecast period.Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
See How Non-alcoholic Steatohepatitis (NASH) Market Demand is Rising in North America Request Free Sample
Geographically, the market is led by North America, where a high prevalence of risk factors and a robust R&D ecosystem create significant demand.
Meanwhile, Asia is projected to witness the fastest growth, with a regional CAGR of 48.0%, fueled by rising awareness and improving healthcare access.
The high unmet medical need across regions is accelerating innovative clinical trial design and the adoption of personalized treatment strategies. This complex disease pathophysiology demands novel treatment paradigms.
For instance, the use of non-invasive biomarkers and tools like transient elastography is enhancing diagnostic capabilities, with some methods demonstrating over 90% accuracy in fibrosis improvement assessment compared to biopsy-proven disease management, thereby helping to achieve nash resolution and other key histological endpoints without invasive procedures.
Market Dynamics
Our researchers analyzed the data with 2025 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
- The strategic landscape of the global non-alcoholic steatohepatitis (nash) market 2026-2030 is increasingly defined by nuanced clinical and commercial questions. Stakeholders are focused on comparing glp-1 analogs for liver fat reduction and evaluating the efficacy of combination therapy in nash resolution. A key consideration is the thr-beta agonist impact on lipid profile analysis, which is critical for patients with comorbidities.
- The role of non-invasive biomarkers in disease monitoring is pivotal, with significant R&D directed at assessing fibrosis improvement with magnetic resonance elastography. For payers and providers, decisions involve the cost-effectiveness of lanifibranor versus obeticholic acid and understanding the long-term clinical outcomes of acetyl-coa carboxylase inhibitors.
- Operational planning must account for the fact that while some therapies show a 25% greater efficacy, their safety profiles may lead to higher discontinuation rates, impacting long-term budgets. Research into the impact of gut-liver axis modulation on inflammation, pediatric nash prevalence and treatment challenges, and managing drug-induced liver injury in nash trials continues to shape future therapeutic strategies.
- The focus remains on achieving long-term cirrhosis prevention and hepatocellular carcinoma risk reduction.
What are the key market drivers leading to the rise in the adoption of Non-alcoholic Steatohepatitis (NASH) Industry?
- The market's primary driver is the rising global prevalence of obesity and associated metabolic syndromes, which are key risk factors for the disease.
- The market's momentum is primarily fueled by a growing understanding of the disease's underlying mechanisms and a robust pipeline targeting them. Significant investment in anti-fibrotic drug development is underway to address pre-cirrhotic liver fibrosis and prevent progressive non-viral liver diseases.
- Advances in metabolic pathway modulation and strategies to control inflammatory cascade inhibition are central to current research. The rising pediatric nash prevalence, which has grown by nearly 10% in some regions, has intensified the need for effective treatments.
- Moreover, advancements in diagnostic technologies have improved early detection rates by 25%, enabling timely intervention.
- This progress is supported by a clearer endpoint validation process and research into drug-induced liver injury, combination therapy approaches, and the role of genetic predisposition factors, creating a strong foundation for market expansion.
What are the market trends shaping the Non-alcoholic Steatohepatitis (NASH) Industry?
- An increasing emphasis on patient engagement and education is emerging as a significant trend, shaping disease awareness and management strategies.
- Key trends are reshaping the therapeutic and diagnostic landscape, with a strong focus on improving patient outcomes and management efficiency. The move toward multidisciplinary patient care is becoming standard, integrating expertise to manage interconnected conditions like metabolic syndrome components and insulin resistance markers.
- This approach, supported by real-world evidence generation, has been shown to improve adherence to treatment regimens by over 20%. Furthermore, as new therapies gain approval, intensive market access negotiations and sophisticated formulary placement strategy are critical for commercial success.
- Digital health solutions are also being integrated for remote monitoring of indicators such as liver enzyme elevation and lipid profile analysis, which can reduce follow-up visit costs by up to 15%, enhancing the commercial viability assessment of new treatments and supporting long-term goals like cirrhosis prevention.
What challenges does the Non-alcoholic Steatohepatitis (NASH) Industry face during its growth?
- A significant challenge constraining market expansion is the historical lack of regulatory-approved therapies specifically for this condition.
- Despite recent breakthroughs, significant challenges persist in developing and commercializing effective therapies. The complexity of achieving validated nash clinical trial endpoints remains a primary hurdle, with clinical trial failure rates being approximately 20% higher than in other therapeutic areas like oncology.
- The development of novel agents such as galectin-3 inhibitors, fibroblast growth factor 21 analogs, and mitochondrial pyruvate carrier inhibitors is hampered by the need for extensive biomarker validation studies and effective patient stratification methods. Furthermore, optimizing diagnostic imaging modalities for accurate liver fat quantification is an ongoing challenge.
- The high cost of R&D for treatments like dual thr-beta/fxr agonists and fatty acid synthase inhibitors, coupled with difficulties in integrating lifestyle modification integration into clinical practice, complicates the path to market.
Exclusive Technavio Analysis on Customer Landscape
The non-alcoholic steatohepatitis (nash) market forecasting report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the non-alcoholic steatohepatitis (nash) market report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.
Customer Landscape of Non-alcoholic Steatohepatitis (NASH) Industry
Competitive Landscape
Companies are implementing various strategies, such as strategic alliances, non-alcoholic steatohepatitis (nash) market forecast, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the industry.
AbbVie Inc. - An evolving portfolio of advanced therapeutics and precision-guided diagnostics targeting liver fibrosis, inflammation, and underlying metabolic dysfunction defines the market's key offerings.
The industry research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:
- AbbVie Inc.
- Bristol Myers Squibb Co.
- Cirius Therapeutics
- Eli Lilly and Co.
- Enanta Pharmaceuticals Inc.
- Enzo Biochem Inc.
- GENFIT SA
- Gilead Sciences Inc.
- Intercept Pharmaceuticals Inc.
- Inventiva S.A.
- Madrigal Pharmaceuticals Inc.
- Merck and Co. Inc.
- Novartis AG
- Novo Nordisk AS
- Pfizer Inc.
- Prometheus Laboratories
- Siemens Healthineers AG
- Takeda Pharmaceutical Ltd.
- Zydus Lifesciences Ltd.
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key industry players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
Recent Development and News in Non-alcoholic steatohepatitis (nash) market
- In September 2024, Eli Lilly presented compelling Phase 2 trial results for tirzepatide, demonstrating significant MASH resolution and fibrosis improvement, positioning the dual GIP and GLP-1 receptor agonist as a formidable future competitor.
- In November 2024, Pfizer Inc. announced a strategic collaboration with a clinical-stage biopharmaceutical company to co-develop a next-generation acetyl-coa carboxylase inhibitor for NASH, involving a substantial upfront payment to accelerate development.
- In January 2025, Boehringer Ingelheim and Zealand Pharma announced positive results from a Phase 2 trial of their dual glucagon/GLP-1 receptor agonist, survodutide, showing significant improvements in liver fibrosis and highlighting the promise of incretin-based mechanisms.
- In March 2025, Madrigal Pharmaceuticals received a landmark accelerated approval from the Food and Drug Administration for Rezdiffra (resmetirom), making it the first therapy specifically approved for the treatment of NASH in adults with moderate to advanced liver fibrosis.
Dive into Technavio’s robust research methodology, blending expert interviews, extensive data synthesis, and validated models for unparalleled Non-alcoholic Steatohepatitis (NASH) Market insights. See full methodology.
| Market Scope | |
|---|---|
| Page number | 279 |
| Base year | 2025 |
| Historic period | 2020-2024 |
| Forecast period | 2026-2030 |
| Growth momentum & CAGR | Accelerate at a CAGR of 47.1% |
| Market growth 2026-2030 | USD 40056.2 million |
| Market structure | Fragmented |
| YoY growth 2025-2026(%) | 41.3% |
| Key countries | US, Canada, Mexico, Germany, UK, France, Italy, The Netherlands, Spain, Russia, China, Japan, India, South Korea, Indonesia, Thailand, Singapore, Australia, UAE, Brazil, South Africa, Saudi Arabia and Turkey |
| Competitive landscape | Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
Research Analyst Overview
- The non-alcoholic steatohepatitis (NASH) market is at a critical inflection point, transitioning from a field of clinical exploration to one of commercial reality. The recent regulatory success for a thyroid hormone receptor-beta agonist has significantly de-risked the development landscape, influencing boardroom-level decisions regarding R&D investment and M&A strategies.
- This progress underscores the viability of targeting diverse mechanisms, from farnesoid x receptor agonist pathways and peroxisome proliferator-activated receptor modulation to acetyl-coa carboxylase inhibitors and apoptosis signal-regulating kinase 1 inhibitor approaches. The focus is now on achieving key histological endpoints like nash resolution and fibrosis improvement to prevent cirrhosis.
- The integration of AI in drug discovery has accelerated the identification of viable targets, with some platforms reducing preclinical timelines for agents like c-c chemokine receptor type 2 antagonist by up to 40%.
- This efficiency is crucial for navigating a complex pipeline that includes stearoyl-coa desaturase-1 inhibitors and caspase inhibitors, ultimately aiming to address the high unmet medical need with effective combination therapy approaches.
What are the Key Data Covered in this Non-alcoholic Steatohepatitis (NASH) Market Research and Growth Report?
-
What is the expected growth of the Non-alcoholic Steatohepatitis (NASH) Market between 2026 and 2030?
-
USD 40.06 billion, at a CAGR of 47.1%
-
-
What segmentation does the market report cover?
-
The report is segmented by Distribution Channel (Offline, and Online), Application (Diagnosis, and Treatment), Product (Vitamin E and pioglitazone, Obeticholic acid (OCA), Lanifibranor, and Others) and Geography (North America, Europe, Asia, Rest of World (ROW))
-
-
Which regions are analyzed in the report?
-
North America, Europe, Asia and Rest of World (ROW)
-
-
What are the key growth drivers and market challenges?
-
Rising prevalence of obesity and metabolic syndrome, Lack of approved therapies
-
-
Who are the major players in the Non-alcoholic Steatohepatitis (NASH) Market?
-
AbbVie Inc., Bristol Myers Squibb Co., Cirius Therapeutics, Eli Lilly and Co., Enanta Pharmaceuticals Inc., Enzo Biochem Inc., GENFIT SA, Gilead Sciences Inc., Intercept Pharmaceuticals Inc., Inventiva S.A., Madrigal Pharmaceuticals Inc., Merck and Co. Inc., Novartis AG, Novo Nordisk AS, Pfizer Inc., Prometheus Laboratories, Siemens Healthineers AG, Takeda Pharmaceutical Ltd. and Zydus Lifesciences Ltd.
-
Market Research Insights
- The market is rapidly evolving from a development-centric phase to a commercial one, shaped by stringent regulatory pathways and the critical need for commercial viability assessment. North America currently represents over 52% of the market's incremental growth, driven by a high unmet medical need and advanced healthcare infrastructure.
- The successful navigation of market access negotiations and securing favorable formulary placement strategy are now paramount for new entrants. Furthermore, the integration of advanced diagnostic imaging modalities has improved patient identification accuracy by over 30% compared to traditional methods.
- This enhancement in precision-guided diagnostics is crucial for effective patient stratification methods and supports the generation of real-world evidence, which is vital for long-term success.
We can help! Our analysts can customize this non-alcoholic steatohepatitis (nash) market research report to meet your requirements.